Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Description:
This in-depth intelligence report provides a comprehensive strategic and financial assessment of SK Bioscience Co., Ltd. (KRX: 302440), a South Korean biopharmaceutical company specializing in recombinant antigen vaccines and CDMO services. Developed under the BBIU framework, the report offers unmatched insight into SK Bioscience’s ownership structure, fiscal performance, clinical pipeline, IP portfolio, regulatory positioning, and international alliances (CEPI, WHO, Gavi).
The analysis includes a granular breakdown of underutilized manufacturing capacity, risks from limited technological diversification, and the company's weak transition into next-generation vaccine platforms (e.g., mRNA, monoclonal antibodies). A special annex outlines a novel industrial synergy model linking SK Bioscience with circular value initiatives (PET-to-paracetamol-to-pavement).
Who it's for:
Venture capital firms, institutional investors, CDMO clients, technology transfer teams, and multinational pharmaceutical strategists evaluating partnerships, licensing opportunities, or acquisition targets in Asia’s vaccine ecosystem.
Highlights:
Financial performance and R&D allocation (FY2022–2024)
Regulatory exposure and compliance status across MFDS, EMA, WHO
Patent landscape: 5 core US patents verified (2024–2025)
CDMO role post-COVID: strategic repositioning scenario
Strategic recommendations (tech acquisition, equity restructuring, IP monetization)
Annex: Circular industrial model for SK Group integration (PET–Paracetamol–Pavement)
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com
Description:
This in-depth intelligence report provides a comprehensive strategic and financial assessment of SK Bioscience Co., Ltd. (KRX: 302440), a South Korean biopharmaceutical company specializing in recombinant antigen vaccines and CDMO services. Developed under the BBIU framework, the report offers unmatched insight into SK Bioscience’s ownership structure, fiscal performance, clinical pipeline, IP portfolio, regulatory positioning, and international alliances (CEPI, WHO, Gavi).
The analysis includes a granular breakdown of underutilized manufacturing capacity, risks from limited technological diversification, and the company's weak transition into next-generation vaccine platforms (e.g., mRNA, monoclonal antibodies). A special annex outlines a novel industrial synergy model linking SK Bioscience with circular value initiatives (PET-to-paracetamol-to-pavement).
Who it's for:
Venture capital firms, institutional investors, CDMO clients, technology transfer teams, and multinational pharmaceutical strategists evaluating partnerships, licensing opportunities, or acquisition targets in Asia’s vaccine ecosystem.
Highlights:
Financial performance and R&D allocation (FY2022–2024)
Regulatory exposure and compliance status across MFDS, EMA, WHO
Patent landscape: 5 core US patents verified (2024–2025)
CDMO role post-COVID: strategic repositioning scenario
Strategic recommendations (tech acquisition, equity restructuring, IP monetization)
Annex: Circular industrial model for SK Group integration (PET–Paracetamol–Pavement)
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com